Experimental compound reduced lung scarring in mice
Mice with drug-induced lung scarring received UCM-17017 at 40 milligrams per kilogram for seven days, reducing collagen deposits compared with a vehicle control.
Limit: Only eight animals were reported for the lung-scarring experiment
Edited by Boris Djordjevic · AgingResearch.News
Mice with bleomycin-induced pulmonary fibrosis, a disease involving lung scarring, received the experimental compound UCM-17017 in an animal experiment. Researchers began dosing two weeks after bleomycin and reported a sample size of eight animals. They gave 40 milligrams per kilogram of body weight by abdominal injection for seven days.
The compound reduced deposits of collagen, a structural protein, to levels similar to those seen with a reference drug. It did not improve weight loss. In separate experiments in human cells grown in the lab, it reduced an enzyme activity used as a sign of senescence in fibroblasts, cells that make connective tissue. Senescence is a state in which cells stop dividing. It also reduced viability, a measure of cell survival, more in senescent human lung cancer cells than in dividing cells.
Why it matters
Age-related pulmonary fibrosis is a target for drugs aimed at senescent cells. The authors said their results support pursuing this approach to drug discovery.
Caveats
The lung benefit was measured through collagen deposits in a chemically induced mouse model, not clinical outcomes in people. The compound did not significantly reduce the measured senescence marker in mouse lungs.
The paper
Universidad Complutense de Madrid
Journal of Medicinal Chemistry, Jul 10, 2026, Open access
